Cargando…
Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
FLT3-ITD mutations occur in 20–30% of AML patients and are associated with aggressive disease. Patients with relapsed FLT3-mutated disease respond well to 2(nd) generation FLT3 TKIs but inevitably relapse within a short timeframe. In this setting, until overt relapse occurs, the bone marrow microenv...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606260/ https://www.ncbi.nlm.nih.gov/pubmed/32409689 http://dx.doi.org/10.1038/s41375-020-0858-1 |
_version_ | 1783604459117477888 |
---|---|
author | Patel, Ami B. Pomicter, Anthony D. Yan, Dongqing Eiring, Anna M. Antelope, Orlando Schumacher, Jonathan A. Kelley, Todd W. Tantravahi, Srinivas K. Kovacsovics, Tibor J. Shami, Paul J. O’Hare, Thomas Deininger, Michael W. |
author_facet | Patel, Ami B. Pomicter, Anthony D. Yan, Dongqing Eiring, Anna M. Antelope, Orlando Schumacher, Jonathan A. Kelley, Todd W. Tantravahi, Srinivas K. Kovacsovics, Tibor J. Shami, Paul J. O’Hare, Thomas Deininger, Michael W. |
author_sort | Patel, Ami B. |
collection | PubMed |
description | FLT3-ITD mutations occur in 20–30% of AML patients and are associated with aggressive disease. Patients with relapsed FLT3-mutated disease respond well to 2(nd) generation FLT3 TKIs but inevitably relapse within a short timeframe. In this setting, until overt relapse occurs, the bone marrow microenvironment facilitates leukemia cell survival despite continued on-target inhibition. We demonstrate that human bone marrow derived conditioned medium (CM) protects FLT3-ITD(+) AML cells from the 2(nd) generation FLT3 TKI quizartinib and activates STAT3 and STAT5 in leukemia cells. Extrinsic activation of STAT5 by CM is the primary mediator of leukemia cell resistance to FLT3 inhibition. Combination treatment with quizartinib and dasatinib abolishes STAT5 activation and significantly reduces the IC(50) of quizartinib in FLT3-ITD(+) AML cells cultured in CM. We demonstrate that CM protects FLT3-ITD(+) AML cells from the inhibitory effects of quizartinib on glycolysis and that this is partially reversed by treating cells with the combination of quizartinib and dasatinib. Using a doxycycline-inducible STAT5 knockdown in the FLT3-ITD(+) MOLM-13 cell line, we show that dasatinib-mediated suppression of leukemia cell glycolytic activity is STAT5-independent and provide a preclinical rationale for combination treatment with quizartinib and dasatinib in FLT3-ITD(+) AML. |
format | Online Article Text |
id | pubmed-7606260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
record_format | MEDLINE/PubMed |
spelling | pubmed-76062602020-11-14 Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms Patel, Ami B. Pomicter, Anthony D. Yan, Dongqing Eiring, Anna M. Antelope, Orlando Schumacher, Jonathan A. Kelley, Todd W. Tantravahi, Srinivas K. Kovacsovics, Tibor J. Shami, Paul J. O’Hare, Thomas Deininger, Michael W. Leukemia Article FLT3-ITD mutations occur in 20–30% of AML patients and are associated with aggressive disease. Patients with relapsed FLT3-mutated disease respond well to 2(nd) generation FLT3 TKIs but inevitably relapse within a short timeframe. In this setting, until overt relapse occurs, the bone marrow microenvironment facilitates leukemia cell survival despite continued on-target inhibition. We demonstrate that human bone marrow derived conditioned medium (CM) protects FLT3-ITD(+) AML cells from the 2(nd) generation FLT3 TKI quizartinib and activates STAT3 and STAT5 in leukemia cells. Extrinsic activation of STAT5 by CM is the primary mediator of leukemia cell resistance to FLT3 inhibition. Combination treatment with quizartinib and dasatinib abolishes STAT5 activation and significantly reduces the IC(50) of quizartinib in FLT3-ITD(+) AML cells cultured in CM. We demonstrate that CM protects FLT3-ITD(+) AML cells from the inhibitory effects of quizartinib on glycolysis and that this is partially reversed by treating cells with the combination of quizartinib and dasatinib. Using a doxycycline-inducible STAT5 knockdown in the FLT3-ITD(+) MOLM-13 cell line, we show that dasatinib-mediated suppression of leukemia cell glycolytic activity is STAT5-independent and provide a preclinical rationale for combination treatment with quizartinib and dasatinib in FLT3-ITD(+) AML. 2020-05-14 2020-11 /pmc/articles/PMC7606260/ /pubmed/32409689 http://dx.doi.org/10.1038/s41375-020-0858-1 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Patel, Ami B. Pomicter, Anthony D. Yan, Dongqing Eiring, Anna M. Antelope, Orlando Schumacher, Jonathan A. Kelley, Todd W. Tantravahi, Srinivas K. Kovacsovics, Tibor J. Shami, Paul J. O’Hare, Thomas Deininger, Michael W. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms |
title | Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms |
title_full | Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms |
title_fullStr | Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms |
title_full_unstemmed | Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms |
title_short | Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms |
title_sort | dasatinib overcomes stroma-based resistance to the flt3 inhibitor quizartinib using multiple mechanisms |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606260/ https://www.ncbi.nlm.nih.gov/pubmed/32409689 http://dx.doi.org/10.1038/s41375-020-0858-1 |
work_keys_str_mv | AT patelamib dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms AT pomicteranthonyd dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms AT yandongqing dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms AT eiringannam dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms AT antelopeorlando dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms AT schumacherjonathana dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms AT kelleytoddw dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms AT tantravahisrinivask dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms AT kovacsovicstiborj dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms AT shamipaulj dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms AT oharethomas dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms AT deiningermichaelw dasatinibovercomesstromabasedresistancetotheflt3inhibitorquizartinibusingmultiplemechanisms |